We are live on ! Find out more
RM

RP Management Portfolio holdings

AUM $139M
1-Year Est. Return 37.98%
This Fund
S&P 500
This Quarter Est. Return
-9.4%
1 Year Est. Return
-37.98%
3 Year Est. Return
+207.8%
5 Year Est. Return
+1,098.05%
10 Year Est. Return
–
AUM
$239M
AUM Growth
+$24.6M
Cap. Flow
+$50.9M
Cap. Flow %
21.31%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$50.9M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
2 Miscellaneous 2.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$153M 64.09%
1,111,111
– –
BCRX icon
2
BioCryst Pharmaceuticals
BCRX
$2.52B
$43M 18%
+3,846,154
New +$50.9M
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$22.9M 9.59%
9,166,667
– –
VIRX
4
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$13.5M 5.65%
3,700
– –
EPZM
5
CALL
DELISTED
Epizyme, Inc
EPZM
$6.37M 2.66%
2,546,134
+14,086
+0.6% +$55.3K

Similar funds

PC
Paradoxiom Capital Stamford, Connecticut $154M AUM
LA
LPF Advisors Sarasota, Florida $122M AUM 3.12% 1-Year Est. Return
TP
Thunderbird Partners London, United Kingdom $113M AUM 8.51% 1-Year Est. Return
SC
Serenity Capital Palo Alto, California $167M AUM
MADFP
Michael A Dubis Financial Planning Middleton, Wisconsin $103M AUM
RM
RCF Management Denver, Colorado $103M AUM
NC
Napatree Capital Westerly, Rhode Island $178M AUM 8.09% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

RP Management's Q4 2021 Portfolio in Review

As of Q4 2021, RP Management held 5 positions worth $239M, up 11% from $214M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

RP Management deployed $50.9M of net new capital in Q4 2021, opening 1 new position and adding to 1 existing holding. Its largest new stake was BioCryst Pharmaceuticals: 3,846,154 shares worth $43M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 94% a quarter earlier, followed by Miscellaneous.

  • RP Management's largest Q4 2021 buy was BioCryst Pharmaceuticals: 3,846,154 shares worth $43M.
  • RP Management's ten largest holdings make up 100% of its $239M portfolio in Q4 2021.
  • RP Management opened 1 new position and closed 0 in Q4 2021.
  • RP Management's portfolio value rose 11% quarter-over-quarter to $239M.

Based on RP Management's 13F filing for Q4 2021, filed 14 Feb 2022.